<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03286634</url>
  </required_header>
  <id_info>
    <org_study_id>ASIA-DS-ALL-2016</org_study_id>
    <nct_id>NCT03286634</nct_id>
  </id_info>
  <brief_title>ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016</brief_title>
  <official_title>Asia-wide, Multicenter Open-label, Phase II Non-randomised Study Involving Children With Down Syndrome Under 21 Year-old With Newly Diagnosed, Treatment naïve Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Hospital Organization Nagoya Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Hospital Organization Nagoya Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the outcome of a prednisolone and low dose methotrexate based protocol in Down
      syndrome children with ALL (DS-ALL) in an Asia-wide study. The treatment protocol was
      modified based upon backbone of Taiwan Pediatric Oncology Group (TPOG)-ALL protocol in which
      risk classification will be guided by level of flow minimal residual disease (MRD) instead.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2027</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>risk stratification-directed chemotherapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event Free Survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Percentage of patients who are event free at 5 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Percentage of patients who survive at 5 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Percentage of patients who are leukemia free at 5 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction failure</measure>
    <time_frame>5 weeks</time_frame>
    <description>Percentage of patients who had failed induction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete remission rate</measure>
    <time_frame>5 weeks</time_frame>
    <description>Percentage of patients who had achieved complete remission at the end of induction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-related adverse events</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Incidence of treatment-related infectious and metabolic complications (throughout various phases of study therapy) and secondary neoplasms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flow MRD at day 15</measure>
    <time_frame>At day 15 of induction therapy</time_frame>
    <description>To assess the prognostic value flow MRD level during induction for DS-ALL.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Down Syndrome</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Childhood Cancer</condition>
  <arm_group>
    <arm_group_label>SR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard Risk (SR) :
CNS 3 or CNS 2 regardless of response OR Time-point #1 (Day 15 induction) Flow MRD ≥ 1% (treatment will not be de-escalated even MRD &lt;0.01% by TP#2) OR Time-point #2 (Day 1 IDMTX/MP of Consolidation) ≥0.01%
SR strategy:
All SR patient will have to receive two doses of anthracycline and 12 L-asparaginase doses during induction except those who are escalated to SR at time point 2 when MRD ≥0.01%.
During the first year of maintenance phase (48 weeks; 4x12 weeks blocks), cyclophosphamide and cytarabine bolus will be administered at 4 weekly interval.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Risk (LR):
Time-point #1 (Day 15 induction) Flow MRD &lt;1% AND Time-point #2 (Day 1 IDMTX/MP of Consolidation) &lt;0.01% AND CNS 1 only
LR strategy:
For LR patients, one dose of anthracycline and 3 doses of L-asparaginase will be omitted during induction.
Following re-induction I, interim maintenance and additional block of re-induction ie. re-induction II prior to maintenance phase will be omitted for LR patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>SR</arm_group_label>
    <arm_group_label>LR</arm_group_label>
    <other_name>DNR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Given PO or IV</description>
    <arm_group_label>SR</arm_group_label>
    <arm_group_label>LR</arm_group_label>
    <other_name>Pred</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>SR</arm_group_label>
    <arm_group_label>LR</arm_group_label>
    <other_name>VCR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>SR</arm_group_label>
    <arm_group_label>LR</arm_group_label>
    <other_name>EPI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E-coli L-asparaginase</intervention_name>
    <description>Given IM or IV</description>
    <arm_group_label>SR</arm_group_label>
    <arm_group_label>LR</arm_group_label>
    <other_name>E-coli L-Asp</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6-Mercaptopurine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>SR</arm_group_label>
    <arm_group_label>LR</arm_group_label>
    <other_name>6-MP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IV, PO or IT</description>
    <arm_group_label>SR</arm_group_label>
    <arm_group_label>LR</arm_group_label>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>Given IT</description>
    <arm_group_label>SR</arm_group_label>
    <arm_group_label>LR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV, IT or SC</description>
    <arm_group_label>SR</arm_group_label>
    <other_name>Ara-C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>SR</arm_group_label>
    <other_name>Cy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Down syndrome diagnosed clinically or cytogenetically (including Mosaic Down)

          -  Newly diagnosed ALL according to WHO 2016 classification.

          -  Age &lt; 21 years old at time of enrollment.

          -  ECOG performance status (PS) score of 0-2.

          -  Written informed consent obtained from legally acceptable representatives.

        Exclusion Criteria:

          -  Second malignancy.

          -  Philadelphia positive ALL.

          -  Mature B-ALL.

          -  Mixed phenotype acute leukemia.

          -  Any previous treatment with cytotoxic chemotherapy excluding treatment for TAM or
             radiation therapy. Patient pre-treated with short term steroid (&lt; 7 days of duration
             within last 1 month prior to treatment start) can be enrolled into this study.

          -  Renal dysfunction with creatinine &gt;2x upper limit of normal (ULN). Patients whose
             creatinine has improved to &lt;2x ULN before treatment commencement can enrol subject to
             discretion of site PI.

          -  Liver dysfunction with direct bilirubin &gt; 5x ULN.

          -  Any serious uncontrolled medical condition or impending end organ dysfunction that
             would impair the ability of the subject to receive protocol therapy, including:

               1. History of coronary arterial disease, cardiomyopathy, heart failure, arrhythmia
                  (other than sinus arrhythmia) or severe cardiac malformation which with residual
                  abnormalities or requires further major corrective surgery within 2 years.

               2. Ongoing uncontrolled hypertension.

               3. Ongoing uncontrolled diabetes mellitus.

               4. Ongoing uncontrolled infection.

               5. History of congenital or acquired immunodeficiency including HIV infection.

               6. History of interstitial pneumonia, pulmonary fibrosis, bronchiectasis or severe
                  pulmonary emphysema.

               7. CNS hemorrhage.

               8. Psychiatric disorder.

               9. Other concurrent active neoplasms.

          -  Pregnant or lactating women.

          -  Doubtful compliance or ability to complete study therapy due to financial, social,
             familial or geographic reason, or in the judgement of site investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allen Yeoh, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University Hospital, Singapore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allen Yeoh, MBBS</last_name>
    <phone>(65) 67724406</phone>
    <email>allen_yeoh@nuhs.edu.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Shatin</city>
        <state>New Territories</state>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chi Kong Li, MBBS</last_name>
      <email>ckli@cuhk.edu.hk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kagoshima University Hospital</name>
      <address>
        <city>Kagoshima</city>
        <zip>890-8544</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yasuhiro Okamoto</last_name>
      <email>okamoto@m2.kufm.kagoshima-u.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hany Arrifin, MBBS</last_name>
      <email>hany@ummc.edu.my</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Subang Jaya Medical Centre</name>
      <address>
        <city>Subang Jaya</city>
        <zip>47500</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hai Peng Lin, MBBS</last_name>
      <email>flslhp@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Lee Lee Chan, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Allen Yeoh, MBBS</last_name>
      <email>allen_yeoh@nuhs.edu.sg</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>KK Women's and Children's Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>229899</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ah Moy Tan, MBBS</last_name>
      <email>tan.ah.moy01@singhealth.com.sg</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Children's Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tsamn Lin Dong, MD</last_name>
      <email>dtlin@ntuh.gov.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10449</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hsi-Che Liu, MD</last_name>
      <email>hsiche@mmh.org.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hopsital, Linkou</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shih-Hsiang Chen, MD</last_name>
      <email>samechen@cgmh.org.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Japan</country>
    <country>Malaysia</country>
    <country>Singapore</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2017</study_first_submitted>
  <study_first_submitted_qc>September 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2017</study_first_posted>
  <last_update_submitted>November 24, 2017</last_update_submitted>
  <last_update_submitted_qc>November 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Down Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

